Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Further Therapeutic Strategies with Guselkumab in Moderate-to-Severe Plaque Psoriasis
2018-001238-16Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of super-responders with PASI <3 at week 68 (groups 2a and 2b). Started Sep 2018; status: active.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2018-001238-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001238-16.